Accutar Biotechnology Inc. a biotechnology company focused on drug discovery using the power of artificial intelligence (AI), today announced that it is resistant to metastatic caster . Announced that the US Food and Drug Administration (FDA) has approved a new drug clinical trial start notification (IND) for AC0176 to treat patients with prostate cancer (mCRPC). AC0176 is an orally administrable chimeric degrading molecule designed to target androgen receptor (AR) degradation with high potency, selectivity, and wide range of mutation coverage. AR is a hormone-controlled transcription factor whose activation plays a vital role in the development and progression of prostate cancer. Accutar is expected to begin enrollment in Phase 1 clinical trials for AC0176 in the first quarter of 2022. Dr. Jie Fan, CEO of Accutar Biotechnology, Inc., said: "We have just entered clinical trials for AC0682, but the IND approval of AC0176 reveals that our AI platform can potentially differentiate clinical candidates, especially complex compounds such as chimeric degradative molecules. It is important once again to prove that we can support and move forward quickly, and the IND approval of AC0176 is the current standard of care for this patient population, second-generation non-steroidal AR. It is crucial in providing new therapeutic candidates based on a different mechanism of action from antagonists. We look forward to the clinical benefits that AC0176 may bring to patients with prostate cancer. I am. " This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AC0176 treatment in patients with mCRPC. About AC0176 AC0176 is an orally administrable investigational drug as a chimeric androgen receptor (AR) -degrading molecule and is a candidate for the treatment of prostate cancer. AC0176 has demonstrated potent and selective AR protein degradation, good pharmacological properties, and promising antitumor activity in animal models while covering a wide range of AR mutations in preclinical studies. About Accutar Biotechnology Accutar is a clinical biotechnology company focused on drug discovery using the power of AI, as well as its application to drug discovery and development of clinically differentiated medicines. Be transformative. For the patient.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!